Search Results - "Price, Matthew J"

Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease by Hill, Jonathan M., Kereiakes, Dean J., Shlofmitz, Richard A., Klein, Andrew J., Riley, Robert F., Price, Matthew J., Herrmann, Howard C., Bachinsky, William, Waksman, Ron, Stone, Gregg W.

“…Coronary calcification hinders stent delivery and expansion and is associated with adverse outcomes. Intravascular lithotripsy (IVL) delivers acoustic pressure…”
Get full text

Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy by Holmes, David R., MD, Kar, Saibal, MD, Price, Matthew J., MD, Whisenant, Brian, MD, Sievert, Horst, MD, Doshi, Shephal K., MD, Huber, Kenneth, MD, Reddy, Vivek Y., MD

“…Abstract Background In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) trial…”
Get full text

The NCDR Left Atrial Appendage Occlusion Registry by Freeman, James V., Varosy, Paul, Price, Matthew J., Slotwiner, David, Kusumoto, Fred M., Rammohan, Chidambaram, Kavinsky, Clifford J., Turi, Zoltan G., Akar, Joseph, Koutras, Cristina, Curtis, Jeptha P., Masoudi, Frederick A.

“…Left atrial appendage occlusion (LAAO) to prevent stroke in patients with atrial fibrillation has been evaluated in 2 randomized trials; post-approval clinical…”
Get full text

Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention by Urban, Philip, Mehran, Roxana, Colleran, Roisin, Angiolillo, Dominick J, Byrne, Robert A, Capodanno, Davide, Cuisset, Thomas, Cutlip, Donald, Eerdmans, Pedro, Eikelboom, John, Farb, Andrew, Gibson, C Michael, Gregson, John, Haude, Michael, James, Stefan K, Kim, Hyo-Soo, Kimura, Takeshi, Konishi, Akihide, Laschinger, John, Leon, Martin B, Magee, P F Adrian, Mitsutake, Yoshiaki, Mylotte, Darren, Pocock, Stuart, Price, Matthew J, Rao, Sunil V, Spitzer, Ernest, Stockbridge, Norman, Valgimigli, Marco, Varenne, Olivier, Windhoevel, Ute, Yeh, Robert W, Krucoff, Mitchell W, Morice, Marie-Claude

“…Identification and management of patients at high bleeding risk undergoing percutaneous coronary intervention are of major importance, but a lack of…”
Get full text

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention by Sibbing, Dirk, Aradi, Daniel, Alexopoulos, Dimitrios, ten Berg, Jurrien, Bhatt, Deepak L., Bonello, Laurent, Collet, Jean-Philippe, Cuisset, Thomas, Franchi, Francesco, Gross, Lisa, Gurbel, Paul, Jeong, Young-Hoon, Mehran, Roxana, Moliterno, David J., Neumann, Franz-Josef, Pereira, Naveen L., Price, Matthew J., Sabatine, Marc S., So, Derek Y.F., Stone, Gregg W., Storey, Robert F., Tantry, Udaya, Trenk, Dietmar, Valgimigli, Marco, Waksman, Ron, Angiolillo, Dominick J.

“…Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary…”
Get full text

Transcatheter Left Atrial Appendage Occlusion in the DOAC Era by Price, Matthew J., Saw, Jacqueline

“…[Display omitted]…”
Get full text

Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study by Wijns, William, Shite, Junya, Jones, Michael R, Lee, Stephen W L, Price, Matthew J, Fabbiocchi, Franco, Barbato, Emanuele, Akasaka, Takashi, Bezerra, Hiram, Holmes, David

“…ILUMIEN I is the largest prospective, non-randomized, observational study of percutaneous coronary intervention (PCI) procedural practice in patients…”
Get full text

Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate by Bonello, Laurent, MD, Tantry, Udaya S., PhD, Marcucci, Rossella, MD, PhD, Blindt, Ruediger, MD, Angiolillo, Dominick J., MD, PhD, Becker, Richard, MD, Bhatt, Deepak L., MD, MPH, Cattaneo, Marco, MD, Collet, Jean Philippe, MD, PhD, Cuisset, Thomas, MD, Gachet, Christian, MD, PhD, Montalescot, Gilles, MD, PhD, Jennings, Lisa K., PhD, Kereiakes, Dean, MD, Sibbing, Dirk, MD, Trenk, Dietmar, PhD, Van Werkum, Jochem W., MD, PhD, Paganelli, Franck, MD, Price, Matthew J., MD, Waksman, Ron, MD, Gurbel, Paul A., MD

“…The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic…”
Get full text

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention by Aradi, Dániel, Kirtane, Ajay, Bonello, Laurent, Gurbel, Paul A, Tantry, Udaya S, Huber, Kurt, Freynhofer, Matthias K, ten Berg, Jurrien, Janssen, Paul, Angiolillo, Dominick J, Siller-Matula, Jolanta M, Marcucci, Rossella, Patti, Giuseppe, Mangiacapra, Fabio, Valgimigli, Marco, Morel, Olivier, Palmerini, Tullio, Price, Matthew J, Cuisset, Thomas, Kastrati, Adnan, Stone, Gregg W, Sibbing, Dirk

“…Although platelet reactivity during P2Y12-inhibitors is associated with stent thrombosis (ST) and bleeding, standardized and clinically validated thresholds…”
Get full text

Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding by Tantry, Udaya S., PhD, Bonello, Laurent, MD, PhD, Aradi, Daniel, MD, PhD, Price, Matthew J., MD, Jeong, Young-Hoon, MD, PhD, Angiolillo, Dominick J., MD, PhD, Stone, Gregg W., MD, Curzen, Nick, BM (hons), PhD, Geisler, Tobias, MD, ten Berg, Jurrien, MD, PhD, Kirtane, Ajay, MD, SM, Siller-Matula, Jolanta, MD, PhD, Mahla, Elisabeth, MD, Becker, Richard C., MD, Bhatt, Deepak L., MD, MPH, Waksman, Ron, MD, Rao, Sunil V., MD, Alexopoulos, Dimitrios, MD, Marcucci, Rossella, MD, PhD, Reny, Jean-Luc, MD, PhD, Trenk, Dietmar, PhD, Sibbing, Dirk, MD, Gurbel, Paul A., MD

“…Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in…”
Get full text

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation by Price, Matthew J., Endemann, Sarah, Gollapudi, Raghava R., Valencia, Rafael, Stinis, Curtiss T., Levisay, Justin P., Ernst, Alissa, Sawhney, Neil S., Schatz, Richard A., Teirstein, Paul S.

“…Aims The aim of this study was to determine whether platelet reactivity on clopidogrel therapy, as measured by a point-of-care platelet function assay, is…”
Get full text

Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry by Price, Matthew J., Valderrábano, Miguel, Zimmerman, Sarah, Friedman, Daniel J., Kar, Saibal, Curtis, Jeptha P., Masoudi, Frederick A., Freeman, James V.

“…Pericardial effusion (PE) is a potential complication of transcatheter left atrial appendage occlusion. The objective of this study was to investigate the…”
Get full text

Assessing the Safety of Early U.S. Commercial Application of Left Atrial Appendage Closure by Saw, Jacqueline, MD, Price, Matthew J., MD

“…[Display omitted]…”
Get full text

Two-Year Outcomes With a Next-Generation Left Atrial Appendage Device: Final Results of the PINNACLE FLX Trial by Doshi, Shephal K, Kar, Saibal, Sadhu, Ashish, Horton, Rodney, Osorio, Jose, Ellis, Christopher, Stone, Jr, James, Shah, Manish, Dukkipati, Srinivas R, Adler, Stuart, Nair, Devi G, Kim, Jamie, Wazni, Oussama, Price, Matthew J, Holmes, Jr, David R, Shipley, Robert, Christen, Thomas, Allocco, Dominic J, Reddy, Vivek Y

“…Background The PINNACLE FLX (Protection Against Embolism for Non-valvular AF [Atrial Fibrillation] Patients: Investigational Device Evaluation of the Watchman…”
Get full text

Predictors of Heightened Platelet Reactivity Despite Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention by Price, Matthew J., MD, Nayak, Keshav R., MD, Barker, Colin M., MD, Kandzari, David E., MD, Teirstein, Paul S., MD

“…Small studies have indicated that drug-drug interactions and such clinical characteristics as diabetes mellitus may increase residual platelet reactivity in…”
Get full text

Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device by Enomoto, Yoshinari, MD, Gadiyaram, Varuna K., MD, Gianni, Carola, MD, PhD, Horton, Rodney P., MD, FHRS, Trivedi, Chintan, MD, MPH, FHRS, Mohanty, Sanghamitra, MD, MBBS, MS, FHRS, Di Biase, Luigi, MD, PhD, FHRS, Al-Ahmad, Amin, MD, CCSD, FHRS, Burkhardt, J. David, MD, FHRS, Narula, Arvin, MD, Janczyk, Gwen, PAC, Price, Matthew J., MD, Afzal, Muhammad R., MD, Atoui, Moustapha, MD, Earnest, Matthew, MD, Swarup, Vijay, MD, FHRS, Doshi, Shephal K., MD, van der Zee, Sarina, MD, Fisher, Rebecca, MD, Lakkireddy, Dhanunjaya R., MD, Gibson, Douglas N., MD, FHRS, Natale, Andrea, MD, FHRS, Reddy, Vivek Y., MD

“…Background In the stroke prevention trials of left atrial appendage closure with the Watchman device (Boston Scientific), a postimplantation antithrombotic…”
Get full text

Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention by Mauri, Laura, Kirtane, Ajay J., Windecker, Stephan, Yeh, Robert W., Dauerman, Harold L., Price, Matthew J., Christen, Thomas, Allocco, Dominic J., Meredith, Ian T., Kereiakes, Dean J.

“…While extended dual antiplatelet therapy (DAPT) with aspirin and a platelet (P2Y12) inhibitor after percutaneous coronary intervention (PCI) reduces the risk…”
Get full text

Safety and efficacy of the next generation Resolute Onyx zotarolimus‐eluting stent: Primary outcome of the RESOLUTE ONYX core trial by Price, Matthew J., Shlofmitz, Richard A., Spriggs, Douglas J., Haldis, Thomas A., Myers, Paul, Popma Almonacid, Alexandra, Maehara, Akiko, Dauler, Michelle, Peng, Yun, Mehran, Roxana

“…Objectives To assess the safety and efficacy of the novel Resolute (R‐) Onyx drug‐eluting stent (DES). Background The R‐Onyx DES consists of a composite wire…”
Get full text

Diabetes Mellitus and Clopidogrel Response Variability by Price, Matthew J., MD

“…[...]the U.S. Food and Drug Administration recommends avoiding concomitant use of the proton pump inhibitors omeprazole and esomeprazole because…”
Get full text

ACIST-FFR Study (Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement) by Fearon, William F, Chambers, Jeffrey W, Seto, Arnold H, Sarembock, Ian J, Raveendran, Ganesh, Sakarovitch, Charlotte, Yang, Lingyao, Desai, Manisha, Jeremias, Allen, Price, Matthew J

“…Measurement of fractional flow reserve (FFR) to guide coronary revascularization lags despite robust supportive data, partly because of the handling…”
Get full text